BlackRock
DNTH icon

BlackRock’s Dianthus Therapeutics DNTH Stock Holding History

BlackRock’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267M Buy
3,175,703
+1,260,467
+66% +$73M ﹤0.01% 1496
2025
Q4 		$78.9M Buy
1,915,236
+575,145
+43% +$22.3M ﹤0.01% 2245
2025
Q3 		$52.7M Sell
1,340,091
-18,690
-1% -$478K ﹤0.01% 2460
2025
Q2 		$25.3M Sell
1,358,781
-257,020
-16% -$4.82M ﹤0.01% 2870
2025
Q1 		$29.3M Sell
1,615,801
-35,081
-2% -$773K ﹤0.01% 2714
2024
Q4 		$36M Buy
1,650,882
+6,063
+0.4% +$156K ﹤0.01% 2669
2024
Q3 		$45M Buy
1,644,819
+41,272
+3% +$1.15M ﹤0.01% 2532
2024
Q2 		$41.5M Buy
1,603,547
+1,556,932
+3,340% +$37.4M ﹤0.01% 2534
2024
Q1 		$1.4M Buy
46,615
+14,309
+44% +$311K ﹤0.01% 4109
2023
Q4 		$336K Buy
32,306
+155
+0.5% +$1.71K ﹤0.01% 4523
2023
Q3 		$440K Buy
32,151
+9,390
+41% +$118K ﹤0.01% 4461
2023
Q2 		$276K Sell
22,761
-6,362
-22% -$72.4K ﹤0.01% 4652
2023
Q1 		$370K Buy
29,123
+183
+0.6% +$2.03K ﹤0.01% 4609
2022
Q4 		$183K Sell
28,940
-17,178
-37% -$304K ﹤0.01% 4878
2022
Q3 		$1.04M Sell
46,118
-3,592
-7% -$98.3K ﹤0.01% 4465
2022
Q2 		$955K Sell
49,710
-83,859
-63% -$2.07M ﹤0.01% 4551
2022
Q1 		$6.2M Sell
133,569
-1,975
-1% -$108K ﹤0.01% 3838
2021
Q4 		$9.61M Sell
135,544
-2,934
-2% -$295K ﹤0.01% 3696
2021
Q3 		$16.1M Buy
138,478
+5,534
+4% +$645K ﹤0.01% 3424
2021
Q2 		$20.8M Buy
132,944
+11,075
+9% +$2.03M ﹤0.01% 3271
2021
Q1 		$23.1M Buy
121,869
+9,278
+8% +$1.56M ﹤0.01% 3107
2020
Q4 		$14.1M Buy
112,591
+2,128
+2% +$241K ﹤0.01% 3189
2020
Q3 		$12M Buy
110,463
+10,374
+10% +$1.23M ﹤0.01% 3124
2020
Q2 		$12M Sell
100,089
-1,204
-1% -$170K ﹤0.01% 3082
2020
Q1 		$10.2M Sell
101,293
-2,363
-2% -$438K ﹤0.01% 2983
2019
Q4 		$25.1M Buy
103,656
+81
+0.1% +$15.1K ﹤0.01% 2753
2019
Q3 		$17M Buy
103,575
+2,111
+2% +$401K ﹤0.01% 2911
2019
Q2 		$23.9M Buy
101,464
+30,504
+43% +$7.54M ﹤0.01% 2750
2019
Q1 		$18.7M Buy
70,960
+36,186
+104% +$6.24M ﹤0.01% 2777
2018
Q4 		$3.17M Buy
34,774
+24,047
+224% +$3.28M ﹤0.01% 3533
2018
Q3 		$2.06M Buy
10,727
+4,477
+72% +$942K ﹤0.01% 3763
2018
Q2 		$1.35M Buy
+6,250
New +$1.41M ﹤0.01% 3858

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock's DNTH Position: Q1 2026 in Review

BlackRock increased its Dianthus Therapeutics (DNTH) stake by 66% in Q1 2026, buying an estimated $73M and bringing the position to 3,175,703 shares worth $267M. The position accounts for ﹤0.01% of the portfolio, ranked #1496.

BlackRock first reported a position in DNTH in Q2 2018 and has held it in 32 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • BlackRock held 3,175,703 shares of Dianthus Therapeutics worth $267M as of Q1 2026.
  • BlackRock bought 1,260,467 Dianthus Therapeutics shares in Q1 2026, an estimated $73M.
  • Dianthus Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #1496 holding.
  • BlackRock first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 32 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.